Key facts
- Highlight Therapeutics’s last known valuation is $39.6M (Feb 2021).
- It has raised $76.2M; the latest was Later Stage VC ($17.5M) in Sep 2025.
- Notable investors include INNVIERTE SICC, European Regional Development Fund (Brandenburg), Buenavista Equity Partners, Advent Life Sciences, Columbus Venture Partners — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Highlight Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Highlight Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Highlight Therapeutics
Developer of RNA-based immuno-oncology therapies designed to combat cancer in patients. The company's therapies recapitulate the effect of viral infection and enhance the therapeutic effect of drugs, enabling medical professionals to promote the speedy recovery of tumors in patients.
- Sector
- Healthcare
- HQ
- Valencia, Spain
- Founded
- 2010
- Employees
- 23
- Website
- highlighttherapeutics.com/
- Ownership
- Privately Held (backing)
Highlight Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Highlight Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Highlight Therapeutics in its N-PORT filings yet. We sweep new filings monthly.